Search results for "HECK"

showing 10 items of 682 documents

PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow c…

2022

Peripheral immune-checkpoint blockade with mAbs to programmed cell death receptor-1 (PD-1) (either nivolumab or pembrolizumab) or PD-Ligand-1 (PD-L1) (atezolizumab, durvalumab, or avelumab) alone or in combination with doublet chemotherapy represents an expanding treatment strategy for metastatic non-small cell lung cancer (mNSCLC) patients. This strategy lays on the capability of these mAbs to rescue tumor-specific cytotoxic T lymphocytes (CTLs) inactivated throughout PD-1 binding to PD-L1/2 in the tumor sites. This inhibitory interactive pathway is a physiological mechanism of prevention against dangerous overreactions and autoimmunity in case of prolonged and/or repeated CTL response to …

immune checkpoint inhibitorsCancer Researchimmune systemNSCLOncologybioinformaticNSLCflow cytometryimmune checkpoint inhibitorNKT; NSCL; bioinformatics; flow cytometry; immune checkpoint inhibitorsNKTbioinformaticsPD1.Frontiers in oncology
researchProduct

Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review

2022

Simple Summary Moving from the achievements of immune checkpoint inhibitors in metastatic lung cancer, the great promise of immunotherapy in resectable early-stage is to make a disease, often lethal until now for frequent post-surgery relapses, more curable. This review focuses on role of immunotherapy in early-stage non-small cell lung cancer. We summarize biological rationale, findings from clinical trials of adjuvant and neoadjuvant immune checkpoint inhibitors, questions about biomarkers and choice of endpoints, aiming to provide up-to-date information useful for clinical decision making. Lung cancer is the leading cause of cancer-related death worldwide. Since prognosis of early-stage …

immune checkpoint inhibitorsCancer Researchlung cancernon-small-cell lung carcinoma (NSCLC)OncologyadjuvantSettore MED/06 - Oncologia Medicaneoadjuvantadjuvant; immune checkpoint inhibitors; immunotherapy; lung cancer; neoadjuvant; non-small-cell lung carcinoma (NSCLC);immune checkpoint inhibitorimmunotherapy
researchProduct

Incidence of mucositis during therapy with PD1-PDL1 type immune checkpoint inhibitors

2020

immune checkpoint inhibitorsmucositiscancer
researchProduct

The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems

2022

Cancer is one of the main causes of disease-related deaths in the world. Although cancer treatment strategies have been improved in recent years, the survival time of cancer patients is still far from satisfied. Cancer immunotherapy, such as Oncolytic virotherapy, Immune checkpoints inhibition, Chimeric antigen receptor T (CAR-T) cell therapy, Chimeric antigen receptor natural killer (CAR-NK) cell therapy and macrophages genomic modification, has emerged as an effective therapeutic strategy for different kinds of cancer. However, many patients do not respond to the cancer immunotherapy which warrants further investigation to optimize this strategy. The clustered regularly interspaced short …

immune checkpoints inhibitionCancer ResearchOncologyoncolytic virusesMini ReviewcancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensimmunotherapyCAR-T therapyCRISPR/Cas9RC254-282Frontiers in Oncology
researchProduct

Classification of current anticancer immunotherapies.

2014

© 2014. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

immunostimulatory cytokinesmedicine.medical_treatmentReviewBioinformaticsDNA-based vaccinesEfficacy0302 clinical medicineCancer immunotherapyNeoplasmspeptide-based vaccines0303 health sciencesPatología//purl.org/becyt/ford/3.1 [https]CANCER3. Good healthMedicina BásicaOncologycheckpoint blockers030220 oncology & carcinogenesisQR180//purl.org/becyt/ford/3 [https]ImmunotherapyCIENCIAS MÉDICAS Y DE LA SALUDmedicine.drug_classInmunologíaadoptive cell transfer; checkpoint blockers; dendritic cell-based interventions; DNA-based vaccines; immunostimulatory cytokines; peptide-based vaccines; oncolytic viruses; Toll-like receptor agonistsMonoclonal antibodydendritic cell-based interventionsToll-like receptor agonistsRC025403 medical and health sciencesImmune systemAntigen[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineAnimalsHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biologyadoptive cell transfer030304 developmental biologyIMMUNOTHERAPIESbusiness.industryCancerImmunotherapymedicine.diseaseR1Oncolytic virusoncolytic virusesImmunologybusinessOncotarget
researchProduct

Kestävyys- ja teholajiurheilijoiden kuormittuminen ja kuormittumisen seuranta lyhyellä aikavälillä

2018

Nikola-Määttä, Sanna (2018). Kestävyys- ja teholajiurheilijoiden kuormittumisen seuranta lyhyellä aikavälillä. Liikuntatieteellinen tiedekunta, Jyväskylän yliopisto, Liikuntafysiologian Pro-Gradu -tutkielma, 69 s. Kuormittumisen seuranta on oleellinen osa urheilijoiden harjoittelua ja valmennusta. Ylikuormitus on yleisempää yksilölajeissa kuin joukkuelajeissa. Kestävyyslajien edustajilla on todettu olevan suurempi riski sairastua ylikuormitustilaan. Lisäksi ylikuormittumista on enemmän aikuisilla miehillä kuin naisilla, mutta toisaalta nuorilla tyttöurheilijoilla on havaittu enemmän ylikuormittumista kuin poikaurheilijoilla. Tässä Pro gradu -työssä on tarkasteltu Vuokatti-Ruka Urheiluakatem…

intensiteettisykevälivaihtelusykehydrokortisoniRMSSDkuormitusCheckMyLevel
researchProduct

Conexión de la ruta de proteinquinasa C con la respuesta a estrés genotóxico

2022

El mantenimiento de la integridad genómica es un aspecto crucial para la supervivencia celular. El checkpoint de integridad del DNA es el mecanismo de vigilancia encargado de detectar la presencia de daño en el DNA y poner en marcha una respuesta celular para mantener la estabilidad genómica. Los componentes centrales del checkpoint son las quinasas sensoras ATM y ATR (Tel1 y Mec1 en S. cerevisiae) y CHK1 Y CHK2 (Chk1 y Rad53 en levadura). La correcta activación del checkpoint depende de la actividad de proteína quinasa C (PKC), tanto en células de levadura como de mamíferos. En este trabajo se ha profundizado en la relación entre PKC y la maquinaria del checkpoint de integridad del DNA, as…

isoforma PKCθestabilidad genómicaPkc1isoforma PKCδUNESCO::CIENCIAS DE LA VIDAruta PKCSaccharomyces cerevisiae:CIENCIAS DE LA VIDA [UNESCO]checkpoint de integridad del DNA
researchProduct

Rhetorical strategies of counter-journalism:How American YouTubers are challenging dominant media election narratives

2021

Standardy i praktyki dziennikarskie, które mają służyć demokratycznej deliberacji w erze cyfryzacji są stałym przedmiotem analiz. Stany Zjednoczone to kraj o długiej tradycji dziennikarstwa śledczego, które wielokrotnie odkrywało szkodliwe działania polityków i biznesmenów. W dobie dominacji nowych mediów, do tych praktyk dziennikarskich dołączyła jeszcze konieczność sprawdzania faktów i kontrowania narracji i twierdzeń propagowanych w upolitycznionych mediach komercyjnych. Niniejszy artykuł poświęcony jest retoryce nowego gatunku kontrdziennikarstwa cyfrowego. Przedstawia wyniki analizy strategii retorycznych i erystycznych zidentyfikowanych w krótkich filmach rozpowszechnianych przez popu…

kontrdziennikarstwokontrowaniekrytykaUS presidential electioncounteringcounter-journalismYouTubecritiqueweryfikowanie faktówamerykańskie wybory prezydenckiefact-checkingRes Rhetorica
researchProduct

Trial Watch: Adoptively transferred cells for anticancer immunotherapy

2017

IF 7.719; International audience; Immunotherapies aimed at strengthening immune effector responses against malignant cells are growing at exponential rates. Alongside, the impressive benefits obtained by patients with advanced melanoma who received adoptively transferred tumor-infiltrating lymphocytes (TILs) have encouraged the scientific community to pursue adoptive cell transfer (ACT)-based immunotherapy. ACT involves autologous or allogenic effector lymphocytes that are generally obtained from the peripheral blood or resected tumors, expanded and activated ex vivo, and administered to lymphodepleted patients. ACT may be optionally associated with chemo- and/or immunotherapeutics, with th…

lcsh:Immunologic diseases. Allergy0301 basic medicinePD-L1Adoptive cell transferBreakthrough therapymedicine.medical_treatmentImmunology[SDV.CAN]Life Sciences [q-bio]/CancerReviewBiologycytotoxic T lymphocytelcsh:RC254-282CD19[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineAntigenPD-L1PD-1medicineImmunology and AllergyCytotoxic T cellNK cellchimeric antigen receptorImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensChimeric antigen receptor3. Good healthimmune checkpoint blockers030104 developmental biologyOncology030220 oncology & carcinogenesisImmunologybiology.proteinlcsh:RC581-607
researchProduct

Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models.

2018

Immune checkpoint blockade (ICB) is currently evaluated in patients with glioblastoma (GBM), based on encouraging clinical data in other cancers, and results from studies with the methylcholanthrene-induced GL261 mouse glioma. In this paper, we describe a novel model faithfully recapitulating some key human GBM characteristics, including low mutational load, a factor reported as a prognostic indicator of ICB response. Consistent with this observation, SB28 is completely resistant to ICB, contrasting with treatment sensitivity of the more highly mutated GL261. Moreover, SB28 shows features of a poorly immunogenic tumor, with low MHC-I expression and modest CD8(+) T-cell infiltration, suggest…

lcsh:Immunologic diseases. Allergy0301 basic medicinemedicine.medical_treatmentGL261ImmunologyOncology and CarcinogenesisMajor histocompatibility complexMalignancylcsh:RC254-282Mutational loadVaccine Related03 medical and health sciences0302 clinical medicineRare DiseasesGliomamedicineImmunology and Allergyddc:576.5sb28mutational loadCancerddc:616biologybusiness.industryBrief ReportSB28glioblastomaNeurosciencesImmunotherapyimmune checkpoint blockadelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseImmune checkpointBlockadeBrain DisordersBrain Cancer030104 developmental biologyOncologygl261030220 oncology & carcinogenesisCancer researchbiology.proteinImmunizationlcsh:RC581-607businessGlioblastomaCD8Immune checkpoint blockadeGlioblastoma
researchProduct